MedTrace Logo

HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors

NCT07296341 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-01-14

No results posted yet for this study

Summary

This study is a randomized, open-label, multicenter Phase II clinical trial designed to evaluate the Safety, Tolerability and Preliminary Efficacy of HRS-4642 Combination with Other Antitumor Therapies in Patients with Solid Tumors

Conditions

  • Locally Advanced or Metastatic Pancreatic Cancer With

Interventions

DRUG

HRS-4642;Adebrelimab Injection; nab-paclitaxel; gemcitabine

HRS-4642 combination with Adebrelimab Injection, nab-paclitaxel in combination with gemcitabine

DRUG

HRS-4642;nab-paclitaxel; gemcitabine

nab-paclitaxel in combination with gemcitabine

Sponsors & Collaborators

  • Shanghai Hengrui Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-08
Primary Completion
2027-10-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07296341 on ClinicalTrials.gov